Cencora, Inc. (NYSECOR) today announced that it plans to release its results for the First Quarter of Fiscal 2025 on Wednesday, February 5, 2025, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on February 5, 2025.
Cencora, Inc. (NYSECOR) today announced the completion of its previously announced acquisition of Retina Consultants of America (“RCA”), a leading management services organization (MSO) of retina specialists.
Cencora, Inc. (NYSECOR) today announced the closing of its public offering of $500,000,000 aggregate principal amount of its 4.625% Senior Notes due December 15, 2027 (the “2027 Notes”), $600,000,000 aggregate principal amount of its 4.850% Senior Notes due December 15, 2029 (the “2029 Notes”) and $700,000,000 aggregate principal amount of its 5.150% Senior Notes due February 15, 2035 (the “2035 Notes” and, together with the 2027 Notes and the 2029 Notes, the “Notes”), in an underwritten registered public offering. The offering was made pursuant to an effective shelf registration statement Cencora filed with the Securities and Exchange Commission (the “SEC”) on November 26, 2024.
Cencora, Inc. (NYSECOR) today announced that it priced $500 million aggregate principal amount of its 4.625% Senior Notes due December 15, 2027 (the “2027 Notes”), $600 million aggregate principal amount of its 4.850% Senior Notes due December 15, 2029 (the “2029 Notes”) and $700 million aggregate principal amount of its 5.150% Senior Notes due February 15, 2035 (the “2035 Notes” and, together with the 2027 Notes and the 2029 Notes, the “Notes”), in an underwritten registered public offering. The offering is being made pursuant to an effective shelf registration statement Cencora filed with the Securities and Exchange Commission (the “SEC”) on November 26, 2024. The offering is expected to close on December 9, 2024, subject to the satisfaction of customary closing conditions. Cencora intends to use the net proceeds from the offering to finance the acquisition of the majority of Retina Consultants of America and related fees and expenses, and for general corporate purposes.
Cencora, Inc. (NYSECOR) today reported that in its fiscal year 2024 fourth quarter ended September 30, 2024, revenue increased 14.7 percent to $79.1 billion. Revenue increased 12.1 percent to $294.0 billion for the fiscal year. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $0.02 for the September quarter of fiscal 2024, compared to $1.72 in the prior year quarter. Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased 16.8 percent to $3.34 in the fiscal fourth quarter. For fiscal year 2024, diluted EPS decreased 11.7 percent to $7.53. For fiscal year 2024, adjusted diluted EPS increased 14.8 percent to $13.76.
Cencora, Inc. (NYSECOR) today announced that it has entered into a definitive agreement to acquire Retina Consultants of America (“RCA”), a leading management services organization (MSO) of retina specialists, from Webster Equity Partners.
Cencora, Inc. (NYSECOR) today announced the appointment of Francois Mandeville as Executive Vice President, Strategy and M&A, and Pawan Verma as Executive Vice President, Chief Data and Information Officer. Both leaders will join Cencora’s enterprise leadership team, bringing their extensive experience and expertise to help advance the company’s pharmaceutical-centric strategy and drive growth for Cencora and its customers.
Walgreens Boots Alliance (WBA) is down 60% from its 52-week high, but improving earnings, cost cuts, and a 9.27% dividend yield signal potential recovery.
